EXL-01 is under clinical development by Exeliom Biosciences and currently in Phase II for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase II drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EXL-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EXL-01 overview
EXL-01 is under development for the treatment of Crohn's disease, gastric cancer, hepatocellular cancer, non-small cell lung cancer, Clostridium difficile infection and ulcerative colitis. It is a microbiome based product comprising of single strain of Faecalibacterium prausnitzii. It is administered through oral route.
It was under development for the treatment of irritable bowel syndrome.
Exeliom Biosciences overview
Exeliom Biosciences (Exeliom) is a clinical-stage biopharmaceutical company that develops and commercializes microbial therapeutics for the treatment of inflammatory bowel diseases. The company’s lead clinical program is a mono-strain microbial product candidate that is being developed utilizing Faecalibacterium prausnitzii, a bacterial species for the treatment of crohn’s disease and ulcerative Colitis. Exeliom develops therapies utilizing single microbial strains that interact with human cells in the gut. The company is funded by Auriga Partners, Sofimac Innovation, Cap Innov’Est and Biocodex among others. It has offices in Dijon and Paris. Exeliom is headquartered in Dijon, France.
For a complete picture of EXL-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
